SK67094A3 - Transdermaly administered system containing acetylsalicylic acid - Google Patents
Transdermaly administered system containing acetylsalicylic acid Download PDFInfo
- Publication number
- SK67094A3 SK67094A3 SK670-94A SK67094A SK67094A3 SK 67094 A3 SK67094 A3 SK 67094A3 SK 67094 A SK67094 A SK 67094A SK 67094 A3 SK67094 A3 SK 67094A3
- Authority
- SK
- Slovakia
- Prior art keywords
- drug delivery
- delivery system
- ask
- acetylsalicylic acid
- pharmaceutically acceptable
- Prior art date
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000011321 prophylaxis Methods 0.000 claims abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 239000011159 matrix material Substances 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 13
- 230000002785 anti-thrombosis Effects 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000000853 adhesive Substances 0.000 claims description 10
- 239000010410 layer Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 9
- 239000003146 anticoagulant agent Substances 0.000 claims description 9
- 238000013271 transdermal drug delivery Methods 0.000 claims description 8
- 239000011241 protective layer Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000037317 transdermal delivery Effects 0.000 claims description 2
- 101100054935 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) alcC gene Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 11
- 208000007536 Thrombosis Diseases 0.000 abstract description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- 239000004793 Polystyrene Substances 0.000 description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 230000035515 penetration Effects 0.000 description 7
- 229920006267 polyester film Polymers 0.000 description 7
- 239000012790 adhesive layer Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- -1 polyethylene terephthalate Polymers 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 239000002221 antipyretic Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 229940100640 transdermal system Drugs 0.000 description 4
- BODMYPYTCKYRSP-UHFFFAOYSA-N 1,1-dioctylcyclohexane Chemical compound CCCCCCCCC1(CCCCCCCC)CCCCC1 BODMYPYTCKYRSP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000001760 anti-analgesic effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001195 polyisoprene Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229920004939 Cariflex™ Polymers 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010048620 Intracardiac thrombus Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 150000002027 dodecanoic acid esters Chemical class 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4142483 | 1991-12-20 | ||
| PCT/EP1992/002914 WO1993012799A1 (fr) | 1991-12-20 | 1992-12-16 | Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK67094A3 true SK67094A3 (en) | 1995-03-08 |
Family
ID=6447817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK670-94A SK67094A3 (en) | 1991-12-20 | 1992-12-16 | Transdermaly administered system containing acetylsalicylic acid |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6264978B1 (fr) |
| EP (1) | EP0617623B1 (fr) |
| JP (1) | JP3748270B2 (fr) |
| KR (2) | KR100267442B1 (fr) |
| AT (1) | ATE217528T1 (fr) |
| AU (1) | AU667067B2 (fr) |
| CA (1) | CA2125662C (fr) |
| CZ (1) | CZ285190B6 (fr) |
| DE (2) | DE4241128C2 (fr) |
| DK (1) | DK0617623T3 (fr) |
| ES (1) | ES2176197T3 (fr) |
| FI (1) | FI113838B (fr) |
| HR (1) | HRP921157A2 (fr) |
| HU (1) | HU221679B1 (fr) |
| IL (1) | IL103917A (fr) |
| NO (1) | NO306599B1 (fr) |
| NZ (1) | NZ246158A (fr) |
| PT (1) | PT617623E (fr) |
| SI (1) | SI9200312A (fr) |
| SK (1) | SK67094A3 (fr) |
| WO (1) | WO1993012799A1 (fr) |
| YU (1) | YU75093A (fr) |
| ZA (1) | ZA922814B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5240917A (en) * | 1991-04-03 | 1993-08-31 | Keimowitz Rudolph M | Suppression of thromboxane levels by percutaneous administration of aspirin |
| WO1994013302A1 (fr) * | 1991-12-20 | 1994-06-23 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer |
| US6071896A (en) * | 1992-06-16 | 2000-06-06 | Gundersen Clinic, Ltd. | Suppression of thromboxane levels by percutaneous administration of aspirin |
| CA2150033A1 (fr) * | 1992-12-07 | 1994-06-23 | Frank Becher | Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour therapie antiplaquettaire et prevention du cancer |
| DE4332093C2 (de) * | 1993-09-22 | 1995-07-13 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Acetylsalicylsäure und Verfahren zu seiner Herstellung |
| DE4429663C2 (de) * | 1994-08-20 | 1997-09-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Hydrolyseschutz |
| AU6709096A (en) * | 1995-07-27 | 1997-02-26 | Cal International Limited | Pharmaceutical preparation for percutaneous absorbtion |
| WO1997004757A1 (fr) * | 1995-07-27 | 1997-02-13 | Cal International Limited | Formulation transdermique a base de nitrate |
| AU6709196A (en) * | 1995-07-27 | 1997-02-26 | Cal International Limited | Transdermal patch containing aspirin |
| DE69635298T2 (de) * | 1995-12-26 | 2006-07-13 | Teikoku Seiyaku K.K. | Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen |
| DE19601487C2 (de) * | 1996-01-17 | 2001-09-13 | Micronas Gmbh | Vorrichtung zum Behandeln von malignen Gewebsveränderungen |
| JPH1112177A (ja) * | 1997-06-25 | 1999-01-19 | Teikoku Seiyaku Co Ltd | 安定なアスピリン含有外用製剤 |
| DE19949252B4 (de) * | 1999-10-13 | 2004-02-12 | Lts Lohmann Therapie-Systeme Ag | Verwendung eines superfiziellen therapeutischen Systems zur topischen Applikation von Acetylsalicylsäure zur Behandlung von Akne-Erkrankungen und Verfahren zu seiner Herstellung |
| JP2001187739A (ja) * | 1999-12-28 | 2001-07-10 | Teikoku Seiyaku Co Ltd | アレルギー性皮膚疾患治療用外用剤 |
| RU2201234C2 (ru) * | 2000-12-05 | 2003-03-27 | Воронежский государственный университет | Полимерный водорастворимый аналог ацетилсалициловой кислоты и способ его получения |
| WO2003018023A1 (fr) * | 2001-08-23 | 2003-03-06 | Bruce Frome | Compositions et methodes permettant de cibler la circulation cerebrale et de traiter une cephalee |
| US20040248858A1 (en) * | 2003-06-09 | 2004-12-09 | Parghi Kaumil H. | Cure for cancer |
| US20060127463A1 (en) * | 2004-12-15 | 2006-06-15 | Nugara Peter N | Composite structure including a low vinyl acetate layer |
| US20060188558A1 (en) * | 2005-02-18 | 2006-08-24 | Mylan Technologies, Inc. | Transdermal systems having control delivery system |
| WO2008007171A1 (fr) | 2006-07-09 | 2008-01-17 | Techfields Biochem Co. Ltd | Promédicaments hydrosolubles à charge positive de l'aspirine |
| US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| AU2008251478B2 (en) * | 2007-05-09 | 2012-01-12 | Buckman Laboratories International, Inc. | ASA sizing emulsions for paper and paperboard |
| CA2691446C (fr) * | 2007-06-04 | 2021-07-06 | Techfields Inc | Promedicaments d'ains a vitesse de penetration cutanee et membranaire tres elevee et leurs nouvelles utilisations medicales |
| KR20200022525A (ko) | 2008-12-04 | 2020-03-03 | 충시 위 | 고투과력을 가진 조성물 및 이의 적용 |
| WO2011076401A1 (fr) | 2009-12-23 | 2011-06-30 | Holger Schankin | Compositions pharmaceutiques sensiblement exemptes d'eau, contenant de l'acide acétylsalicylique |
| KR102332837B1 (ko) | 2012-01-18 | 2021-12-01 | 테크필즈 파마 코., 엘티디. | 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3996934A (en) * | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| FR2297612A1 (fr) | 1975-01-20 | 1976-08-13 | Moorleghem Guy Van | Procede de fabrication d'un produit analgesique a usage externe |
| US4012508A (en) | 1975-02-03 | 1977-03-15 | Burton Verna M | Topical composition and method |
| US4219548A (en) | 1978-09-01 | 1980-08-26 | The Procter & Gamble Company | Topical anti-inflammatory composition |
| FR2496459A1 (fr) | 1980-12-19 | 1982-06-25 | Astier Laboratoires Docteur P | Composition pharmaceutique sous forme d'un gel contenant de l'acide acetylsalicylique |
| US4460368A (en) * | 1981-10-29 | 1984-07-17 | Almedco, Inc. | Trans-dermal medication system |
| IL68965A (en) | 1983-06-13 | 1987-02-27 | Rafa Labor Ltd | Topical pharmaceutical preparation comprising acetylsalicylic acid for the treatment of dermatological disorders |
| US4640689A (en) | 1983-08-18 | 1987-02-03 | Drug Delivery Systems Inc. | Transdermal drug applicator and electrodes therefor |
| DE3583698D1 (de) | 1984-04-23 | 1991-09-12 | Kao Corp | Perkutaner absorptions-beschleuniger und diesen enthaltendes praeparat. |
| JPS61167615A (ja) | 1985-01-18 | 1986-07-29 | Teisan Seiyaku Kk | 薬剤投与方法 |
| US4810699A (en) | 1987-02-20 | 1989-03-07 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them |
| JPH01203336A (ja) | 1988-02-09 | 1989-08-16 | Teikoku Seiyaku Kk | 経皮・口腔粘膜適用製剤 |
| JPH01242521A (ja) | 1988-03-23 | 1989-09-27 | Nikko Kemikaruzu Kk | 経皮吸収性を高めた消炎鎮痛薬組成物 |
| US4975269A (en) | 1989-07-31 | 1990-12-04 | Leonard Chavkin | Shelf stable aspirin solutions |
| WO1992020343A1 (fr) * | 1991-04-03 | 1992-11-26 | Gunderson Medical Foundation, Ltd. | Abaissement des taux de thromboxane par administration percutanee d'aspirine |
-
1992
- 1992-10-30 HR HR921157A patent/HRP921157A2/hr not_active Application Discontinuation
- 1992-11-10 SI SI19929200312A patent/SI9200312A/sl unknown
- 1992-11-29 IL IL10391792A patent/IL103917A/en not_active IP Right Cessation
- 1992-12-07 DE DE4241128A patent/DE4241128C2/de not_active Expired - Fee Related
- 1992-12-16 DE DE59209956T patent/DE59209956D1/de not_active Expired - Fee Related
- 1992-12-16 PT PT93900057T patent/PT617623E/pt unknown
- 1992-12-16 SK SK670-94A patent/SK67094A3/sk unknown
- 1992-12-16 DK DK93900057T patent/DK0617623T3/da active
- 1992-12-16 KR KR1019940702176A patent/KR100267442B1/ko not_active Expired - Fee Related
- 1992-12-16 US US08/256,065 patent/US6264978B1/en not_active Expired - Fee Related
- 1992-12-16 WO PCT/EP1992/002914 patent/WO1993012799A1/fr not_active Ceased
- 1992-12-16 AT AT93900057T patent/ATE217528T1/de not_active IP Right Cessation
- 1992-12-16 CA CA002125662A patent/CA2125662C/fr not_active Expired - Fee Related
- 1992-12-16 NZ NZ246158A patent/NZ246158A/en unknown
- 1992-12-16 AU AU31589/93A patent/AU667067B2/en not_active Ceased
- 1992-12-16 ES ES93900057T patent/ES2176197T3/es not_active Expired - Lifetime
- 1992-12-16 HU HU9401849A patent/HU221679B1/hu not_active IP Right Cessation
- 1992-12-16 EP EP93900057A patent/EP0617623B1/fr not_active Expired - Lifetime
- 1992-12-16 JP JP51140593A patent/JP3748270B2/ja not_active Expired - Fee Related
- 1992-12-16 CZ CZ941456A patent/CZ285190B6/cs not_active IP Right Cessation
- 1992-12-18 ZA ZA922814A patent/ZA922814B/xx unknown
-
1993
- 1993-11-18 KR KR1019950702301A patent/KR100267359B1/ko not_active Expired - Fee Related
- 1993-12-02 YU YU75093A patent/YU75093A/sh unknown
-
1994
- 1994-03-22 US US08/216,089 patent/US5861170A/en not_active Expired - Lifetime
- 1994-06-17 NO NO942325A patent/NO306599B1/no not_active IP Right Cessation
- 1994-06-17 FI FI942922A patent/FI113838B/fi active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK67094A3 (en) | Transdermaly administered system containing acetylsalicylic acid | |
| Monkhouse et al. | Transdermal drug delivery-problems and promises | |
| CA1309661C (fr) | Systeme d'administration transdermiques | |
| JP2009173679A (ja) | 部分的ドーパミン−ｄ２作用薬の投与用の経皮治療吸収システム | |
| US6716877B2 (en) | Method to treat chronic heart failure and/or elevated cholesterol levels | |
| FI120719B (fi) | Menetelmä asetyylisalisyylihappoa sisältävän transdermaalisen järjestelmän valmistamiseksi | |
| CA2006425C (fr) | Systeme therapeutique transdermique contenant de la norpseudoephedrine comme ingredient actif | |
| SI9400023A (sl) | Transdermalni sistem dajanja, vsebujoč acetilsalicilno kislino za antitrombotsko terapijo in profilakso proti raku | |
| WO1994013302A1 (fr) | Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer |